197 related articles for article (PubMed ID: 34561275)
21. Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report.
de Joode K; Veenbergen S; Kransse C; Kortleve D; Debets R; Mathijssen RHJ; Joosse A; Schreurs MWJ; Van der Veldt AAM
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36750254
[TBL] [Abstract][Full Text] [Related]
22. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
Anagnostou V; Bruhm DC; Niknafs N; White JR; Shao XM; Sidhom JW; Stein J; Tsai HL; Wang H; Belcaid Z; Murray J; Balan A; Ferreira L; Ross-Macdonald P; Wind-Rotolo M; Baras AS; Taube J; Karchin R; Scharpf RB; Grasso C; Ribas A; Pardoll DM; Topalian SL; Velculescu VE
Cell Rep Med; 2020 Nov; 1(8):100139. PubMed ID: 33294860
[TBL] [Abstract][Full Text] [Related]
23. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
[TBL] [Abstract][Full Text] [Related]
24. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Vera Aguilera J; Paludo J; McWilliams RR; Zhang H; Li Y; Kumar AB; Failing J; Kottschade LA; Block MS; Markovic SN; Dong H; Dronca RS; Yan Y
Melanoma Res; 2020 Aug; 30(4):364-375. PubMed ID: 32404734
[TBL] [Abstract][Full Text] [Related]
25. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
Sheng Y; Tong L; Geyu L
Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
[TBL] [Abstract][Full Text] [Related]
26. Single-cell analysis of peripheral CD8
Khojandi N; Connelly L; Piening A; Hoft SG; Pherson M; Donlin MJ; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2023 Feb; 72(2):397-408. PubMed ID: 35907015
[TBL] [Abstract][Full Text] [Related]
27. uPAR
Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
[TBL] [Abstract][Full Text] [Related]
28. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
30. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract][Full Text] [Related]
31. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.
Aquilanti E; Brastianos PK
Neurosurgery; 2020 Sep; 87(3):E281-E288. PubMed ID: 32302389
[TBL] [Abstract][Full Text] [Related]
33. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
[TBL] [Abstract][Full Text] [Related]
34. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
35. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
McDonald MA; Sanghvi P; Bykowski J; Daniels GA
BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients.
Thaiss WM; Gatidis S; Sartorius T; Machann J; Peter A; Eigentler TK; Nikolaou K; Pichler BJ; Kneilling M
Cancer Immunol Immunother; 2021 May; 70(5):1263-1275. PubMed ID: 33130917
[TBL] [Abstract][Full Text] [Related]
37. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.
Clark PA; Sriramaneni RN; Jin WJ; Jagodinsky JC; Bates AM; Jaquish AA; Anderson BR; Le T; Lubin JA; Chakravarty I; Arthur IS; Heinze CM; Guy EI; Kler J; Klar KA; Carlson PM; Kim KM; Kuo JS; Morris ZS
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690669
[TBL] [Abstract][Full Text] [Related]
38. Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.
Gebhardt C; Simon SCS; Weber R; Gries M; Mun DH; Reinhard R; Holland-Letz T; Umansky V; Utikal J
Cell Immunol; 2021 Feb; 360():104274. PubMed ID: 33383383
[TBL] [Abstract][Full Text] [Related]
39. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
40. MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy.
Jiang X; Dudzinski S; Beckermann KE; Young K; McKinley E; J McIntyre O; Rathmell JC; Xu J; Gore JC
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]